Researcher Urges Stem Cell Trials In U.S. Instead Of China
This article was originally published in PharmAsia News
A U.S. stem cell researcher is calling on fellow scientists to conduct their clinical trials in the United States instead of China. Wise Young of Rutgers University, who once began five clinical trials in China, told a conference he changed his mind about trials there when he discovered that some Americans had wanted to be in the trial so much they volunteered to go to China to be in them. Young urged U.S. trials even though he acknowledged they were cheaper to conduct in China. The problem, he said, was there is no source of funding for U.S. trials. (Click here for more
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.